Merck KGaA: strategic cooperation with Britain's F-star.
(CercleFinance.com) - German pharmaceuticals company Merck KGaA signed on Monday a strategic cooperation agreement with British biopharmaceutical company F-star to develop and market five biospecific immuno-oncology antibodies.
Merck said the collaboration will further strengthen its immuno-oncology pipeline and commitment to discover breakthrough cancer therapies.
The deal includes exclusive development and marketing rights to F-star's pre-clinical lead asset FS118, which is designed to block pathways commonly used by cancer cells to evade the immune system.
It is expected that Merck will pay up to 115 million euros in upfront, R&D funding and milestone payments over the first two years, and may make further payments upon exercising its option and based on milestone payments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Merck said the collaboration will further strengthen its immuno-oncology pipeline and commitment to discover breakthrough cancer therapies.
The deal includes exclusive development and marketing rights to F-star's pre-clinical lead asset FS118, which is designed to block pathways commonly used by cancer cells to evade the immune system.
It is expected that Merck will pay up to 115 million euros in upfront, R&D funding and milestone payments over the first two years, and may make further payments upon exercising its option and based on milestone payments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.